Table 2

Demographic data, type of cancer, ICI molecules and tumour response according to irAE occurrence

Rheumatic irAEs (n=35) n (%)Non-rheumatic irAEs (n=137) n (%)No irAEs (n=368) n (%)
Age, mean (SD)63.8 (11.9)65.5 (12.8)64.0 (12.9)
Gender
 Male23 (65.7)95 (69.3)253 (68.7)
 Female12 (34.3)42 (30.6)115 (31.2)
Tumour type
 Melanoma16 (45.7)83 (62.0)150 (40.7)
 Merkel1 (2.8)0 (0)4 (1.0)
 Lung12 (34.2)17 (12.4)103 (27.9)
 Renal6 (17.1)13 (9.4)55 (14.9)
 Urothelial0 (0)2 (1.4)12 (3.2)
 Head and neck0 (0)11 (8.0)18 (4.8)
 Blood cancer0 (0)3 (2.1)12 (3.2)
 Gastrointestinal/liver0 (0)7 (5.1)11 (2.9)
 Lung+head and neck0 (0)1 (0.7)2 (0.5)
 Glioblastoma0 (0)0 (0)1 (0.2)
Cancer therapy
 Anti-CTLA-40 (0)3 (2.1)2 (0.5)
 Anti-PD-1/PD-L130 (85.7)82 (59.8)305 (82.8)
 Sequential or combined5 (14.2)52 (37.9)61 (16.5)
Best tumour response
 Responders30 (85.7)103 (75.1)130 (35.3)
  Complete response3 (8.5)14 (10.2)15 (4.0)
  Partial response11 (31.4)33 (24.0)45 (12.2)
  Stable disease16 (45.7)56 (40.8)70 (19.0)
 Non-responders5 (14.2)28 (20.4)192 (52.1)
 Unknown0 (0)6 (4.3)46 (12.5)
  • CTLA-4, cytotoxic T-lymphocyte-associated protein 4; ICI, immune checkpoint inhibitor; irAEs, immune-related adverse effects; PD-1, programmed cell death protein 1; PD-L1, PD-1 ligand 1.